Korro Bio, Inc.
KRRO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KRRO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KRRO
Korro Bio, Inc. is a biopharmaceutical company developing RNA editing oligonucleotide therapies for rare and prevalent diseases, with lead programs targeting Alpha-1 Antitrypsin Deficiency and Urea Cycle Disorders.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$190.1M
Cash Runway
19.8 moLead Asset
aatd program (Preclinical)
Next Catalyst
Phase2_Start · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 2 clinical trials · 1 catalyst for Korro Bio, Inc..
Korro Bio, Inc. is a biopharmaceutical company developing RNA editing oligonucleotide therapies for rare and prevalent diseases, with lead programs targeting Alpha-1 Antitrypsin Deficiency and Urea Cycle Disorders.
- Korro Bio is developing a new class of genetic medicines based on RNA editing, using an oligonucleotide approach to achieve a precise adenosine-to-inosine change [sec · filed 2026-03-13].
- The company has two lead programs: KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) and KRRO-121 for Urea Cycle Disorders (UCDs) [sec · filed 2024-11-21][sec · filed 2026-08-19].
- KRRO-121 received ethics committee submission in Australia to initiate a first-in-human Phase 1/2 clinical trial for UCDs [sec · filed 2026-08-19].
- As of June 30, 2026, Korro Bio reported cash and equivalents of $24.9M, zero revenue, and a net loss of $18.9M [sec].
- The company has a research collaboration and license agreement with Novo Nordisk [sec · filed 2025-11-12].
What works
- Korro Bio's RNA editing platform offers a differentiated approach that may provide increased specificity and tunability compared to DNA editing, potentially expanding the reach of genetic medicines [sec · filed 2026-03-13].
- The company has advanced two programs into clinical development (KRRO-110 for AATD and KRRO-121 for UCDs), demonstrating platform progress [sec · filed 2024-11-21][sec · filed 2026-08-19].
- A research collaboration with Novo Nordisk provides external validation and potential resources for development [sec · filed 2025-11-12].
What to weigh
- Korro Bio has no approved products and has generated zero revenue as of June 30, 2026, with a net loss of $18.9M in the latest quarter [sec].
- The company's cash position of $24.9M as of June 30, 2026, may be limited to fund ongoing clinical trials and operations without additional financing [sec].
- Clinical development risks are inherent, including potential delays, regulatory hurdles, and competition from other RNA-targeting therapies [sec · filed 2026-03-09].
From the filings
Quoted directly from source documents.
Korro Bio is developing RNA editing therapies using an oligonucleotide approach.
“We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases.”
SEC filings · March 13, 2026
Korro Bio has a collaboration with Novo Nordisk.
“status of the research collaboration and license agreement with Novo Nordisk”
SEC filings · November 12, 2025
Catalyst timeline
- 2026-09-01 · Phase 2 Start: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study — The company is expected to initiate a Phase 1/2 clinical trial for KRRO-121 in Urea Cycle Disorders, with the trial design including randomized, double-blind, placebo-controlled, single- and multiple-ascending dose cohorts.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Korro Bio has no marketed products and reported zero revenue as of June 30, 2026, with a net loss of $18.9M [sec].
- Limited cash runway — Cash and equivalents of $24.9M as of June 30, 2026, may be insufficient to fund all planned development without additional capital [sec].
- Clinical and regulatory risks — Pre-clinical and clinical studies are subject to delays, failures, and regulatory uncertainties common in biopharmaceutical development [sec · filed 2026-03-09].
- Dependence on platform technology — The RNA editing platform is novel and unproven in late-stage trials, with no guarantee of successful translation to approved therapies [sec · filed 2026-03-13].
What to watch
- Initiation of the Phase 1/2 clinical trial for KRRO-121 in Urea Cycle Disorders, following ethics committee submission in Australia [sec · filed 2026-08-19].
- Progress of KRRO-110 for Alpha-1 Antitrypsin Deficiency, which received clinical trial approval in Australia in November 2024 [sec · filed 2024-11-21].
- Future financing events given the limited cash position of $24.9M as of June 30, 2026 [sec].
- Updates on the Novo Nordisk collaboration and any potential pipeline expansion [sec · filed 2025-11-12].
Sources: Catalysts · Competitor trials · News · SEC filings · Generated August 27, 2026 · How we verify sources →
Run Korro Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Korro Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
19.8 months
OCF -$17M · Net income -$19M
Lead: Phase 1/Phase 2
5 candidates
1 upcoming, next in ~2d
12 buys · 24 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
95
Total value held
$106.6M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 1,538,296 | $17.4M |
| balyasny asset management l.p. | 1,040,054 | $11.8M |
| affinity asset advisors, llc | 706,904 | $8.0M |
| vanguard capital management llc | 621,826 | $7.0M |
| adar1 capital management, llc | 540,054 | $6.1M |
| blackrock, inc. | 460,006 | $5.2M |
| driehaus capital management llc | 450,045 | $5.1M |
| tcg crossover management, llc | 416,301 | $4.7M |
| siren, l.l.c. | 347,718 | $3.9M |
| 72 investment holdings, llc | 276,831 | $3.1M |
Showing top 10 of 95 institutional holders of Korro Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 8.7%
- Days to cover
- 7.3
- Shares short
- 1,117,429
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KRRO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Korro Bio, Inc.?
Korro Bio, Inc. is a biopharmaceutical company developing RNA editing oligonucleotide therapies for rare and prevalent diseases, with lead programs targeting Alpha-1 Antitrypsin Deficiency and Urea Cycle Disorders.
What is Korro Bio, Inc.'s lead drug candidate?
Korro Bio, Inc.'s most advanced tracked candidate is aatd program (Preclinical) for Alpha-1 antitrypsin deficiency (AATD).
What is Korro Bio, Inc.'s next catalyst?
Korro Bio, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study" — expected September 1, 2026.
Who is the CEO of Korro Bio, Inc.?
Dr. Ram Aiyar MBA, Ph.D. is the chief executive officer of Korro Bio, Inc. (KRRO).
Where is Korro Bio, Inc. headquartered?
Korro Bio, Inc. (KRRO) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.